A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 1 Diabetes

In brief

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Key facts

Study ID

NCT05794581

Run by

Carmot Therapeutics, Inc.

People needed

32

Starts

2023-03-21

Expected to finish

2024-04-06

Last updated by the study team

2024-12-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Female or male adults with Type 1 diabetes
• Ages 18-65 years
• Type 1 DM for at least 3 years
• Using an insulin pump or multiple daily injections (MDI) for at least 3 months
• BMI 25.0 - 35.0

You may not qualify if…

• Significant medical history
• Uncontrolled diabetes
• History of surgical treatment for weight loss
• History of malignancy

Where it is running

• Carmot Clinical Research Unit 101 — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.